Evidence map›Paper›PMID 27193825›Full record

ArticleScientific reports2016

GRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic Neuronal Vulnerability.

Minchao He, Prabhakar Singh, Shaowu Cheng, Qiang Zhang, Wei Peng, XueFeng Ding, Longxuan Li, Jun Liu, Richard T Premont, Dave Morgan and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Targeting GRK5 for Treating Chronic Degenerative Diseases.International journal of molecular sciences · 2021
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Minchao HeLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Prabhakar SinghLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Shaowu ChengLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Qiang ZhangLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Wei PengLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
XueFeng DingLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Longxuan LiLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Jun LiuLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Richard T PremontDepartment of Medicine, Duke Univ. Med. Center, Durham, NC 27710, USA.
Dave MorganThe Johnnie B. Byrd Alzheimer's Center &Research Institute, Tampa, FL 33620, USA.
Jeffery M BurnsDepartment of Neurology, University of Kansas Medical College, Kansas City, KS 66170, USA.
Russell H SwerdlowDepartment of Neurology, University of Kansas Medical College, Kansas City, KS 66170, USA.
William Z SuoLaboratory for Alzheimer's Disease and Aging Research, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.

Funding

University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SWERDLOW, RUSSELL H. · 2011 to 2020
$16.6M
New Strategy to Fight Selective Cholinergic Neuronal Loss in Alzheimer DiseaseI01BX001067 · VA · KANSAS CITY VA MEDICAL CENTER · PI SUO, WILLIAM Z. · 2012 to 2015
–
BLRD VA I01 BX001067NIA NIH HHS P30 AG035982
6 · The paper itself

Abstract

Why certain diseases primarily affect one specific neuronal subtype rather than another is a puzzle whose solution underlies the development of specific therapies. Selective basal forebrain cholinergic (BFC) neurodegeneration participates in cognitive impairment in Alzheimer's disease (AD), yet the underlying mechanism remains elusive. Here, we report the first recapitulation of the selective BFC neuronal loss that is typical of human AD in a mouse model termed GAP. We created GAP mice by crossing Tg2576 mice that over-express the Swedish mutant human β-amyloid precursor protein gene with G protein-coupled receptor kinase-5 (GRK5) knockout mice. This doubly defective mouse displayed significant BFC neuronal loss at 18 months of age, which was not observed in either of the singly defective parent strains or in the wild type. Along with other supporting evidence, we propose that GRK5 deficiency selectively renders BFC neurons more vulnerable to degeneration.

Indexed as

Alzheimer DiseaseAnimalsBasal ForebrainCholinergic NeuronsDementiaDisease Models, AnimalG-Protein-Coupled Receptor Kinase 5HumansMice, KnockoutMice, TransgenicG-Protein-Coupled Receptor Kinase 5Grk5 protein, mouse

Identifiers

PMID27193825
PMCPMC4872166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.